- Advances in immune checkpoint inhibitors for hepatocellular carcinoma
-
Ji Won Han, Su-Hyung Park
-
J Liver Cancer. 2021;21(2):139-145. Published online September 30, 2021
-
DOI: https://doi.org/10.17998/jlc.2021.09.24
-
-
3,581
Views
-
99
Downloads
-
3
Citations
-
Abstract
PDF
- Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immune checkpoint blockades do not derive clinical benefit. Thus, there remains an urgent need for novel immunotherapeutic strategies with improved therapeutic efficacy. Here we review recent studies of immune checkpoint blockade in HCC, providing the necessary basis for the rational design of immunotherapy.
-
Citations
Citations to this article as recorded by
- Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies
Logan Muzyka, Nicolas K. Goff, Nikita Choudhary, Michael T. Koltz International Journal of Molecular Sciences.2023; 24(13): 10456. CrossRef - Integrative analysis of lactylation-related genes and establishment of a novel prognostic signature for hepatocellular carcinoma
Diankui Cai, Xiaoqing Yuan, D. Q. Cai, Ang Li, Sijia Yang, Weibang Yang, Jinxin Duan, Wenfeng Zhuo, Jun Min, Li Peng, Jinxing Wei Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11517. CrossRef - Editorial on immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
Samantha M Ruff, Timothy M Pawlik Immunotherapy.2023; 15(16): 1323. CrossRef
|